Table 4. Descriptive statistics of absolute risks, number needed to treat (NNT), and number needed to harm (NNH) for incident ischemic stroke and major hemorrhage across treatment and placebo arms stratified by high and low SPI-II scores.
Results reported from the unstratified cohort are abstracted from the original POINT trial results.
| SPI-II stratum | Treatment arm (n) | Absolute stroke risk | NNT | Absolute major hemorrhage risk | NNH |
|---|---|---|---|---|---|
| Unstratified cohort | Aspirin (2,430) | 6.3% | 56 | 0.41% | 186 |
| Clopidogrel plus aspirin (2,411) | 4.6% | 0.95% | |||
| Low (SPI-II ≤3) | Aspirin (1,402) | 4.41% | 131 | 0.36% | 331 |
| Clopidogrel plus aspirin (1,362) | 3.65% | 0.66% | |||
| High (SPI-II >3) | Aspirin (1,028) | 9.20% | 36 | 0.48% | 119 |
| Clopidogrel plus aspirin (1,049) | 6.40% | 1.32% |